FDA Approves Astellas’ VEZOAH, the First Non-Hormonal Treatment for Menopause-Related Vasomotor Symptoms

May 22, 2023

On May 13, 2023, Astellas’ VEOZAH was approved by the FDA. VEOZAH, also known as fezolinetant, is the first non-hormonal treatment for moderate to severe vasomotor symptoms in women with menopause. Vasomotor symptoms are the most common symptoms of menopause, affecting between 60-80% of women.They include hot flashes and night sweats, and are thought to be due to an imbalance of estrogen and neurokinin B. Unlike estrogen supplication, VEZOAH targets neurokinin B receptors in the temperature regulation center of the brain, the hippocampus. Three ENCORE Research Group centers participated in the pivotal SKYLIGHT trials to investigate efficacy and safety of VEZOAH: the Fleming Island Center for Clinical Research, St. Johns Center for Clinical Research, and Nature Coast Clinical Research – Crystal River. These three centers also participated in the SKYLIGHT 4 trial to study long-term safety. 



Encore logo

As a proven clinical research organization, we take every precaution to ensure the safety of and maximize the value for our research volunteers. Qualified doctors, nurses and study coordinators on staff provide support and care throughout the research trial. Participation is always voluntary. We appreciate the time and effort that research volunteers bring to this important process.

Copyright 2023 ENCORE Research Group